Table of Contents
WASHINGTON, D.C. – The National Pharmaceutical Council (NPC), a 70-year-old health policy research organization, today announced Jen Norton, senior vice president, head of U.S. Patient and Market Access, Takeda, will serve as chair of NPC’s board of directors for 2025. Norton served on NPC’s Board as vice chair in 2024, and previously served in several leadership roles on NPC’s board of directors and executive committee.
“Jen’s deep expertise on the biopharmaceutical industry landscape has helped countless leaders better understand how this industry works and what levers will help patients access medicines,” said John M. O’Brien, president and chief executive officer. “She also understands the importance of timely, clear, policy-relevant research, which in 2025 will be more important than ever. I am grateful to her for her past leadership and excited for her continued leadership as board chair.”
Norton’s career has been dedicated to educating decision-makers about how the healthcare marketplace intersects with prescription drug prices and patient access. She has been in her current role with Takeda since 2023, where she oversees the Patient and Market Access team. Prior to joining Takeda, she held numerous roles of increasing responsibility in Value & Access with Amgen, Market Access & Reimbursement with Biogen, and Pricing with Vertex Pharmaceuticals. Additionally, she previously served as a nonresident senior scholar at the Leonard D. Schaeffer Institute for Public Policy & Government Service.
“There has never been a more important time for NPC’s work,” said Norton. “Given the policy conversations ahead of us in 2025, quality policy-relevant research and effective communication of the data and evidence are critical. My career has focused on educating about and advocating for a system that helps patients access the medical breakthroughs they need, and I look forward to leading NPC as board chair as the organization works to educate stakeholders about what the research says.”
NPC’s board of directors also elected its executive committee for 2025, including:
- Rekha Ramesh, MPP, vice president, U.S. Policy, Gilead Sciences (vice chair)
- Bruce Wilson, vice president, U.S. Oncology Care & Access, AstraZeneca (treasurer, Audit & Budget Committee Chair)
- Christine Marsh, senior vice president, Value & Access, Boehringer Ingelheim (Immediate Past Chair)
- Jeremy Allen, head, Government Affairs, Spark Therapeutics (Member at Large)
In addition to the executive committee, the board of directors re-appointed Chris Leibman, senior vice president, Value, Access, Public Policy, and Government Affairs of Biogen, to continue serving as Chair of the Board-Level Research Committee in 2025.
“Our industry is now at a moment where, for the first time, policy risk is as big as clinical or regulatory risk for manufacturers,” said O’Brien. “I am grateful to the board of directors and to the executive committee for their leadership that drives NPC’s ability to conduct policy-relevant research and communicate it with impact.”
